<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Wakelee, Heather</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Remarkable Progress Made in Systemic Therapy of NSCLC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">27-28</style></pages><abstract><style  face="normal" font="default" size="100%">During the past 50 years, substantial progress has been made in the treatment of the most common type of lung cancer, non—small cell lung cancer (NSCLC). This article discusses adjuvant therapy in NSCLC, the treatment of locally advanced stage III NSCLC, as well as progress in the treatment of advanced NSCLC.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>